Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a 5-year survival rate of 9%. Major obstacles to successful treatment of pancreatic cancer are the immunosuppressive tumor microenvironment (TME) and antigenic complexity or heterogeneity. Programmed death-ligand 1 (PD-L1) is expr...

Full description

Bibliographic Details
Main Authors: Ching-Yao Yang, Ming Huei Fan, Carol H. Miao, Yi Jen Liao, Ray-Hwang Yuan, Chao Lien Liu
Format: Article
Language:English
Published: Elsevier 2020-06-01
Series:Molecular Therapy: Oncolytics
Subjects:
ACR
CAR
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770520300723